Alzheimer’s Monoclonal Antibodies Fail to Deliver Meaningful Results

Alzheimer’s drugs offer little benefit, major review finds – and the reasons go deeper than the science

PeopleImages/Shutterstock.comHow is it possible to spend tens of billions of dollars developing drugs to treat a serious disease that affects millions of people, and yet end up with something that does not work? This is a mystery that has bedevilled Alzheimer’s research for years. A new review of the evidence has concluded that the leading class of Alzheimer’s drugs “probably result in little to no difference” in a range of measures, including r…

Alzheimer’s monoclonal antibodies fail to deliver meaningful results

Despite reducing amyloid plaques, antibody treatments for Alzheimer's fail to improve cognition, highlighting critical gaps in current therapeutic approaches.

Do anti-amyloid drugs actually work? - Health Care Today

More than 55 million people worldwide are living with Alzheimer’s disease, estimates suggest. Treatment for Alzheimer’s disease currently includes medications, such as anti-amyloid drugs that work to remove amyloid-beta plaques from the brain of those with early Alzheimer’s disease. A new study says that anti-amyloid medications may not have any clinically meaningful positive effects, and may increase the risk of swelling and bleeding in the bra…